Are AstraZeneca plc, Eco Animal Health Group plc and Advanced Medical Solutions Group plc the top healthcare picks right now?

Should investors seeking healthcare companies look no further than AstraZeneca plc (LON: AZN), Eco Animal Health Group plc (LON: EAH) and Advanced Medical Solutions Group plc (LON: AMS)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With global stock markets likely to be volatile, healthcare companies are set to become increasingly popular. That’s because they can offer defensive prospects, while also having impressive growth potential.

One company that has stuttered somewhat on the growth front in recent years is AstraZeneca (LSE: AZN). In fact, its bottom line has fallen heavily as a loss of patents on key drugs has hurt sales, but with an acquisition programme set to deliver growth over the long run, AstraZeneca could become a more in-demand stock in the coming years.

While its growth rate has been disappointing in the past, AstraZeneca has remained a strong defensive play. It has a beta of 0.9 and with its earnings being less dependent on the wider economy than is the case for many of its index peers, the company’s shares could become more in demand. That’s especially the case if uncertainty surrounding the global economy increases and investors decide to adopt a more risk-off attitude in the coming months.

Growth and more growth

While AstraZeneca’s bottom line has fallen in recent years, Advanced Medical Solutions (LSE: AMS) has been able to record a rise in its earnings in each of the last five years. In fact, they’ve increased at an annualised rate of almost 13% during the period and looking ahead, further growth is on the horizon.

Certainly, a forecast of 3% earnings growth for the year to 31 December 2016 may be somewhat disappointing, but with an 8% increase forecast for next year, investor sentiment towards Advanced Medical Solutions could improve. That’s especially the case since its most recent annual results showed that it’s making good progress across all parts of its business. Notably, its LiquiBand tissue adhesive range recorded strong performance in the US, while its upbeat R&D product pipeline could allow it to deliver impressive earnings growth over the medium-to-long term.

Bright future

Meanwhile, Eco Animal Health (LSE: EAH) has delivered a stunning share price rise since the turn of the year. The animal pharmaceuticals specialist is up by 20%, at least partly due to multiple pieces of positive news flow regarding regulatory approval for the company’s products. They should provide Eco Animal Health with improved profit growth prospects in future years, with its forecasts for the next two years indicating that further share price rises are on the horizon.

For example, Eco Animal Health is expected to record a rise in its bottom line of 19% in the current year, followed by a further increase of 18% next year. These figures have the potential to cause a step change in investor sentiment towards Eco Animal Health and with its shares trading on a price-to-earnings growth (PEG) ratio of just 1.3, there’s significant upside potential on offer.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Advanced Medical Solutions, AstraZeneca, and ECO Animal Health Group. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »